Stereotactic ablative body radiotherapy (SABR)

Topic Status Complete

Stereotactic ablative body radiotherapy (SABR) for oligoprogressive disease.

Summary

 

Health Technology Wales researchers searched for evidence on the clinical effectiveness and cost effectiveness of Stereotactic ablative body radiotherapy (SABR) to treat oligoprogressive disease. Based on the evidence, HTW’s Assessment Group decided not to progress this topic to full appraisal.

Topic Exploration Report

TER368 07.2022

TER
View PDF

Access our guidance

Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it.
  • We may like to contact you by email to find out more about how you used the documents.

  • This field is for validation purposes and should be left unchanged.